{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:01:14Z","timestamp":1789704074962,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":6164,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1093\/annonc\/mdg050","type":"journal-article","created":{"date-parts":[[2003,2,3]],"date-time":"2003-02-03T16:06:47Z","timestamp":1044288407000},"page":"333-337","source":"Crossref","is-referenced-by-count":145,"title":["Taxane-induced nail changes: incidence, clinical presentationand outcome"],"prefix":"10.1016","volume":"14","author":[{"given":"A.M.","family":"Minisini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.","family":"Sobrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mansutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg050_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel and docetaxel: not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0015","first-page":"507","article-title":"The taxanes: an update","volume":"356","author":"Crown","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdg050_bb0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by Taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdg050_bb0025","series-title":"Cancer: Principles and Practice of Oncology","first-page":"431","article-title":"Antimicrotubule agents","author":"Rowinsky","year":"2001"},{"key":"10.1093\/annonc\/mdg050_bb0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel and docetaxel: not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0035","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (Taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdg050_bb0040","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1200\/JCO.1998.16.5.1811","article-title":"Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B9264","volume":"16","author":"Venook","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0093-7754(01)90129-0","article-title":"New cytotoxic agents and schedules for advanced breast cancer","volume":"28","author":"Burstein","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0050","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdg050_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.6-suppl_3-26","article-title":"Weekly docetaxel in breast cancer: applying clinical data to patient therapy","volume":"6","author":"Baselga","year":"2001","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdg050_bb0060","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/JCO.2001.19.22.4216","article-title":"Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer","volume":"19","author":"Perez","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0065","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial","volume":"19","author":"Hainsworth","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0070","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdf027","article-title":"Phase II study of weekly docetaxel in patients with metastatic breast cancer","volume":"13","author":"Aihara","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0169-5002(00)00122-7","article-title":"Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routinely daily practice","volume":"29","author":"Mattson","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdg050_bb0085","first-page":"253","article-title":"Phase II study of docetaxel in inoperable advanced non small cell lung cancer","volume":"87","author":"Robinet","year":"2000","journal-title":"Bull Cancer"},{"key":"10.1093\/annonc\/mdg050_bb0090","first-page":"83","article-title":"Efficacy of docetaxel in non-small cell lung cancer in patients previously treated with platinum-containing chemotherapy","volume":"17","author":"Robinet","year":"2000","journal-title":"Rev Mal Respir"},{"key":"10.1093\/annonc\/mdg050_bb0095","first-page":"4721","article-title":"Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer","volume":"20","author":"Shin","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdg050_bb0100","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0959-8049(99)00122-7","article-title":"Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group","volume":"35","author":"Sj\u00f6str\u00f6m","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 17","key":"10.1093\/annonc\/mdg050_bb0105","first-page":"45","article-title":"Preliminary evaluation of short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer","volume":"26","author":"Wah Sinibaldi","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0110","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl 12","key":"10.1093\/annonc\/mdg050_bb0115","first-page":"27","article-title":"Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer","volume":"25","author":"Nabholtz","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjc.1998.24","article-title":"Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours","volume":"77","author":"Pronk","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg050_bb0125","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1023\/A:1008434626876","article-title":"Dose-intensified weekly paclitaxel induces multiple nail disorders","volume":"9","author":"L\u00fcftner","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0130","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1997.15.3.1071","article-title":"Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors","volume":"15","author":"Pronk","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0135","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/00001813-199611000-00012","article-title":"A phase II trial of docetaxel in advanced non-small cell lung cancer","volume":"7","author":"Saarinen","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdg050_bb0140","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/oxfordjournals.annonc.a058909","article-title":"Phase II study with docetaxel (Taxotere\u00ae) in advanced soft tissue sarcomas of the adult","volume":"5","author":"Van Hoesel","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0145","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a058907","article-title":"A phase II trial of docetaxel (Taxotere\u00ae) in second line treatment with chemotherapy for advanced breast cancer","volume":"5","author":"Ten Bokkel Huinink","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0150","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1023\/A:1012557528952","article-title":"Weekly docetaxel (Taxotere\u00ae) in patients with metastatic breast cancer","volume":"12","author":"Stemmler","year":"2001","journal-title":"Ann Oncol"},{"issue":"6 Suppl 13","key":"10.1093\/annonc\/mdg050_bb0155","first-page":"17","article-title":"Docetaxel (Taxotere) an overview of first-line monotherapy","volume":"22","author":"Trudeau","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0160","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2367::AID-CNCR22>3.0.CO;2-#","article-title":"Onycholysis as a complication of systemic chemotherapy. Report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature","volume":"88","author":"Hussain","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg050_bb0165","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2133.2002.46824.x","article-title":"Nail changes due to docetaxel","volume":"146","author":"Pavithran","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdg050_bb0170","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0140-6736(00)04210-0","article-title":"Nail changes secondary to docetaxel","volume":"357","author":"Wasner","year":"2001","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdg050_bb0175","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2133.2000.03692.x","article-title":"Subungual abscess: a new ungual side-effect related to docetaxel therapy","volume":"143","author":"Vanhooteghem","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdg050_bb0180","first-page":"146","article-title":"Nail alterations secondary to paclitaxel therapy","volume":"10","author":"Almagro","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1093\/annonc\/mdg050_bb0185","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1345\/aph.18307","article-title":"Onycholysis associated with weekly administration of paclitaxel","volume":"33","author":"Flory","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1093\/annonc\/mdg050_bb0190","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000018132","article-title":"Nail changes secondary to docetaxel (Taxotere)","volume":"198","author":"Correia","year":"1999","journal-title":"Dermatology"},{"key":"10.1093\/annonc\/mdg050_bb0195","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0248-8663(98)80108-2","volume":"19","author":"Auvinet","year":"1998","journal-title":"Yellow nails. Rev M\u00e9d Interne"},{"key":"10.1093\/annonc\/mdg050_bb0200","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1023\/A:1008218824342","article-title":"Onycholysis in patients treated with docetaxel","volume":"9","author":"Obermair","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg050_bb0205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/archderm.134.9.1167","article-title":"Nail bed dyschromia secondary to docetaxel therapy","volume":"134","author":"Jacob","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdg050_bb0210","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000246166","article-title":"Docetaxel-induced subungual hemorrhage","volume":"194","author":"Vanhooteghem","year":"1997","journal-title":"Dermatology"},{"key":"10.1093\/annonc\/mdg050_bb0215","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/archderm.1997.03890470146034","article-title":"Docetaxel chemotherapy induces transverse superficial loss of the nail plate","volume":"133","author":"Llombart-Cussac","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdg050_bb0220","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199707173370305","article-title":"Nail changes after chemotherapy","volume":"337","author":"Slee","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdg050_bb0225","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00873811","article-title":"Cutaneous manifestations of Taxol therapy","volume":"13","author":"Link","year":"1995","journal-title":"Invest New Drugs"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/2\/333\/360217\/mdg050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T01:52:39Z","timestamp":1582163559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419453271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S0923753419453271"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg050","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}